Cas:79537-70-5 tert-butyl N-(3-acetylphenyl)carbamate manufacturer & supplier

We serve Chemical Name:tert-butyl N-(3-acetylphenyl)carbamate CAS:79537-70-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

tert-butyl N-(3-acetylphenyl)carbamate

Chemical Name:tert-butyl N-(3-acetylphenyl)carbamate
CAS.NO:79537-70-5
Synonyms:AB3280;tert-butyl 3-acetylphenylcarbamate
Molecular Formula:C13H17NO3
Molecular Weight:235.27900
HS Code:2924299090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:55.40000
Exact Mass:235.12100
LogP:3.30920

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like AB3280 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl 3-acetylphenylcarbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,AB3280 Use and application,tert-butyl 3-acetylphenylcarbamate technical grade,usp/ep/jp grade.


Related News: Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. tert-butyl N-(3-acetylphenyl)carbamate manufacturer Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. tert-butyl N-(3-acetylphenyl)carbamate supplier Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December. tert-butyl N-(3-acetylphenyl)carbamate vendor Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. tert-butyl N-(3-acetylphenyl)carbamate factory Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.